Form 4: InMed Pharmaceuticals CFO Netta Jagpal Reports Stock Option Grant

InMed Pharmaceuticals' Chief Financial Officer, Netta Jagpal, was granted 3,750 stock options on December 20, 2024, which vest monthly over 36 months.

Summary

• Netta Jagpal, the Chief Financial Officer of InMed Pharmaceuticals, was granted 3,750 employee stock options on December 20, 2024.
• These options have an exercise price of $4.14 and will vest in equal monthly installments over a 36-month period.
• The options expire on December 19, 2029.
• Following the transaction, Ms. Jagpal beneficially owns 6,250 derivative securities.
• The document also notes that InMed Pharmaceuticals underwent a 1-for-20 reverse stock split on November 14, 2024.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral to positive as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule of 36 months encourages long-term commitment from the CFO.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when there are changes in beneficial ownership by company insiders. The granting of stock options is a typical form of executive compensation.

Comparison to Industry Standards

• Stock option grants are a common practice for compensating executives in publicly traded companies, particularly in the pharmaceutical and biotech industries.
• The vesting schedule of 36 months is also a standard practice to ensure long-term alignment of interests.
• The exercise price of $4.14 is specific to InMed's stock and would need to be compared to other companies in the same sector to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant may have a slightly positive impact on shareholder sentiment as it aligns the CFO's interests with those of the shareholders.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, Netta Jagpal, InMed Pharmaceuticals, executive compensation, reverse stock split